Literature DB >> 12468014

Radioligand studies: imaging and quantitative analysis.

Adriaan A Lammertsma1.   

Abstract

Radioligand studies enable visualisation and measurement of molecular pathways and pharmacokinetic processes. Using positron emission tomography, accurate measurements of the time course of radioligand uptake and clearance can be obtained. A tracer kinetic model is needed to derive physiological or pharmacokinetic parameters from these tissue time-activity curves. In addition, an input function that indicates delivery to the tissue is required. Usually this will be the arterial plasma curve. For receptor studies, where binding potential is the parameter of interest, it might also be possible to avoid arterial sampling provided a tissue can be defined that is devoid of receptors.

Mesh:

Substances:

Year:  2002        PMID: 12468014     DOI: 10.1016/s0924-977x(02)00100-1

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  11 in total

1.  Predicting brain concentrations of drug using positron emission tomography and venous input: modeling of arterial-venous concentration differences.

Authors:  Stina Syvänen; Gunnar Blomquist; Lieuwe Appel; Margareta Hammarlund-Udenaes; Bengt Långström; Mats Bergström
Journal:  Eur J Clin Pharmacol       Date:  2006-08-08       Impact factor: 2.953

Review 2.  Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development: designing informative human pharmacology studies.

Authors:  Adam Cohen
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

3.  Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine.

Authors:  Jeffrey S Stehouwer; Mark M Goodman
Journal:  PET Clin       Date:  2009-01

Review 4.  Quantitative in vivo cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imaging.

Authors:  Kenneth M Tichauer; Yu Wang; Brian W Pogue; Jonathan T C Liu
Journal:  Phys Med Biol       Date:  2015-07-02       Impact factor: 3.609

5.  Blood-brain barrier penetration of zolmitriptan--modelling of positron emission tomography data.

Authors:  Mats Bergström; Roger Yates; Anders Wall; Matts Kågedal; Stina Syvänen; Bengt Långström
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-02       Impact factor: 2.745

6.  Kinetic models for analysing myocardial [(11)C]palmitate data.

Authors:  Hugo W A M de Jong; Luuk J Rijzewijk; Mark Lubberink; Rutger W van der Meer; Hildo J Lamb; Jan W A Smit; Michaëla Diamant; Adriaan A Lammertsma
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-27       Impact factor: 9.236

7.  Altered 5-HT(2A) receptor binding after recovery from bulimia-type anorexia nervosa: relationships to harm avoidance and drive for thinness.

Authors:  Ursula F Bailer; Julie C Price; Carolyn C Meltzer; Chester A Mathis; Guido K Frank; Lisa Weissfeld; Claire W McConaha; Shannan E Henry; Sarah Brooks-Achenbach; Nicole C Barbarich; Walter H Kaye
Journal:  Neuropsychopharmacology       Date:  2004-06       Impact factor: 7.853

8.  PET kinetics of radiolabeled antidepressant, [N-methyl-11C]mirtazapine, in the human brain.

Authors:  Ole L Munk; Donald F Smith
Journal:  EJNMMI Res       Date:  2011-12-15       Impact factor: 3.138

9.  Molecular Neurobiology of Depression: PET Findings on the Elusive Correlation with Symptom Severity.

Authors:  Donald F Smith; Steen Jakobsen
Journal:  Front Psychiatry       Date:  2013-03-04       Impact factor: 4.157

10.  Novel Approach to Repeated Arterial Blood Sampling in Small Animal PET: Application in a Test-Retest Study with the Adenosine A1 Receptor Ligand [(11)C]MPDX.

Authors:  Jürgen W A Sijbesma; Xiaoyun Zhou; David Vállez García; Martin C Houwertjes; Janine Doorduin; Chantal Kwizera; Bram Maas; Peter Meerlo; Rudi A Dierckx; Riemer H J A Slart; Philip H Elsinga; Aren van Waarde
Journal:  Mol Imaging Biol       Date:  2016-10       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.